What Happens When You Stop a GLP-1

The trials that followed people after they stopped taking a GLP-1 are, in some ways, the most informative ones in the whole field. They tell you what these drugs are: treatment for a chronic condition, whose effect largely depends on continuing to take them.

People are often told this in passing, at the end of a consultation, in the tone of a disclaimer. It deserves more, because it is the fact most likely to shape whether starting makes sense for you. Our complete guide to GLP-1 medications covers the class generally; this article deals with the withdrawal data.

What the discontinuation studies found

Several trials in this class included a phase in which participants stopped the drug, or were randomly assigned to stop while others continued. The findings have been consistent enough that they are no longer really disputed.

When treatment stopped, weight rose again. Not immediately and not all at once, but steadily, and over roughly a year most of what had been lost came back for most participants. The cardiometabolic improvements that had accompanied the weight loss — blood pressure, glycaemic measures, lipid profile, waist circumference — moved back toward where they had started. In trials where one group continued treatment and another stopped, the two groups' curves separated clearly, with the continuing group holding their loss and the stopping group returning toward baseline.

Two things about the shape of this. It was not universal — some individuals maintained a good deal of their loss, and the average conceals real variation. And regain was generally not instantaneous; there is usually a window after stopping in which nothing dramatic happens, which sometimes leads people to conclude they have got away with it.

Why regain happens

This is the part that matters most, because how you explain it to yourself determines what you do next.

Body weight is regulated. The brain, principally the hypothalamus, integrates signals about energy stores and food intake from hormones including leptin, ghrelin, GLP-1, GIP and PYY, and adjusts appetite and energy expenditure to defend a range. That system did not evolve to help anyone reach a target weight. It evolved to resist the loss of energy stores, because for almost all of human history losing energy stores was dangerous.

When weight falls, that system responds. Hormones that suppress appetite decrease. Ghrelin, which stimulates it, tends to rise. Energy expenditure falls by more than the reduction in body mass alone accounts for. Studies of people who have lost substantial weight have found some of these changes persisting long after the loss itself, which is why maintaining a reduced weight is a harder task than reaching it.

A GLP-1 medication works, in part, by acting on that regulatory system while it is present. Remove the drug and the system returns to defending the weight it was defending before. Hunger comes back. The constant background preoccupation with food that many people describe going quiet on treatment — what patients call food noise — tends to come back too, and people frequently report that as the most disorienting part of stopping.

Note what is absent from that account. Nothing about willpower, motivation or character. The person is the same person; the biology they are negotiating with has changed. Anyone who has lost weight repeatedly and regained it repeatedly has been running this experiment on themselves for years, usually while being told the result was their fault.

What this implies about treating obesity as chronic

The clinical framing that follows from the data is that obesity behaves like a chronic condition, and that medications which treat it behave like treatments for a chronic condition.

The comparison usually offered is to blood pressure medication, and it holds up reasonably well. An antihypertensive lowers blood pressure while it is being taken. Stop it and blood pressure returns to where it was. Nobody describes that as the drug failing, or the patient failing.

The comparison is not perfect. Blood pressure treatment is not accompanied by an assumption that the patient should eventually manage without it, and weight-management treatment usually is — by patients, by clinicians and by insurers. That assumption is cultural rather than clinical.

What the chronic framing does not mean is that everyone must take these drugs forever. It means the expectation of a short course producing a permanent result is not supported by the evidence, and planning as though it were is how people end up blindsided.

Reasons people stop, and how to think about each

Cost or loss of coverage

The most common reason by a distance, and the least discussed clinically. If coverage is likely to end at a known point, that is worth raising at the start rather than at the moment it happens. A planned reduction with support in place is a better position than an abrupt stop when a prescription cannot be filled.

Side effects

Some people cannot tolerate these medications at any useful dose. Switching between agents, or holding at a lower dose, resolves this for some people and not for others. Our article on managing GLP-1 side effects covers what tends to help and, importantly, the symptoms that mean treatment should stop rather than continue.

Pregnancy or planning pregnancy

These medications are not for use in pregnancy, and stopping is required rather than optional. Timing should be planned with a clinician well in advance — see who should not take a GLP-1.

Having reached a goal

Understandable, and the one most likely to end in regain, because reaching a weight does not change the physiology defending the previous one. If this is the reason, it deserves the most detailed planning of the lot.

Simply wanting to be off medication

A legitimate preference, and not one anyone needs to justify. Better acted on with a clinician's involvement than alone.

Having a realistic conversation about duration

Useful questions to put to a prescriber, ideally before starting rather than a year in:

• What does the follow-up data actually show about stopping this drug, and what should I expect?
• If I do well, what does the plan look like at one year? At three?
• Is a lower maintenance dose an option, and what is known about that?
• What happens if my insurance stops covering this — what are my options at that point?
• What would make you recommend stopping?
• If I stop, what monitoring and support is in place afterwards?

A clinician who cannot engage with the last three is treating this as a transaction. Expect an honest answer about the limits of the evidence, too: these drugs have not been in wide use for weight management long enough for anyone to speak confidently about decades of continuous treatment.

What actually helps if you stop

Nobody can promise that any of this prevents regain, and the honest summary is that the evidence for maintenance strategies after GLP-1 discontinuation is thinner than the evidence for the drugs themselves. What is reasonably supported:

• Keep the resistance training. Lean mass is the part of body composition you have most influence over, and it is worth defending regardless of what the scale does. Our article on muscle loss covers this in detail.
• Keep protein high. Protein is more satiating than the alternatives, which matters more once appetite returns.
• Stay in contact with a clinician. Monitoring after stopping is not fussiness; catching an upward trend early leaves more options than noticing it two years later.
• Expect appetite to return and plan for it. Being surprised by hunger is worse than being ready for it.
• Treat regain as information, not verdict. If weight returns, that is data about the condition. Restarting treatment is a normal clinical option, not an admission of anything.

The point of knowing this before you start

None of this is an argument against these medications. They are effective treatments for a condition that has been badly served by decades of advice that did not work. It is an argument for going in with an accurate picture, so that a year from now nothing about the situation is a surprise.

If you want to discuss what long-term treatment would actually look like — including what happens if it stops — that is a reasonable thing to raise at a first appointment rather than a last one. Our weight management service is set up for ongoing care rather than one-off prescribing, and you can book a consultation to have that conversation with a licensed clinician. These are prescription medications, and a clinician may conclude they are not appropriate for you.